Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RPA1 | P27694 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558118 | 0.88 | GCGR (0.55) | LMNAKDM4ECYP1A2MAPTRAB9A | |
| SCHEMBL4391202 | 0.86 | CASP1 (0.40) | LMNACYP2A6KDM4ECYP1A2HSD17B10 | |
| SCHEMBL3550447 | 0.81 | GOT1 (0.47) | LMNAKDM4ECYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL11223011 | 0.81 | LMNA (0.61) | LMNACYP2A6KDM4ECYP1A2HSD17B10 | |
| SCHEMBL3580504 | 0.79 | NPC1 (0.42) | KDM4ECYP1A2HSD17B10ALDH1A1MAPK1 | |
| SCHEMBL4805776 | 0.79 | KDM4E (0.38) | LMNACYP2A6KDM4ECYP1A2HSD17B10 | |
| SCHEMBL4395903 | 0.78 | GCGR (0.46) | LMNAKDM4EMAPK1CASP1RAB9A | |
| SCHEMBL4046888 | 0.78 | PTGS2 (0.40) | KDM4ECYP1A2HSD17B10ALDH1A1MAPK1 | |
| SCHEMBL3570121 | 0.77 | NPC1 (0.47) | LMNAKDM4ECYP1A2HSD17B10ALDH1A1 | |
| SCHEMBL3569381 | 0.77 | CNR2 (0.42) | LMNAKDM4ECYP1A2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891074-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1891074-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100022526-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629342-B2 | Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| EP-2121628-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008089934-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-07-31 | — | — | WO | disclosed |
| EP-1891074-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006138682-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| EP-1697371-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| WO-2005063762-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287323-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | LMNA 4393/4885CYP2A6 325/4885KDM4E 1178/4885 |
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | LMNA 3471/4885CYP2A6 441/4885KDM4E 1176/4885 |
| US-20100022526-A1 | PYRIDAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | CYP4Z1, CYP1A2, CYP1A1 | LMNA 3036/4885CYP2A6 90/4885KDM4E 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.